Eyedrops pulled by CVS, Target made by barefoot workers in India

Tainted eyedrops yanked from pharmacy shelves over fears they could cause infections and even blindness were made in a factory in India where workers walked around barefoot and safety test results were faked, according to an explosive report.

The 26 over-the-counter products — sold as store brands at retailers including CVS, Rite Aid, Walmart and Target — came from a company in Navi Mumbai called Kilitch Healthcare India Ltd., according to a Bloomberg investigation.

On Oct. 25, the Food & Drug Administration issued a recall on the more than two dozen eyedrop brands after agency investigators found unsanitary conditions at the India plant and “positive bacterial test results from environmental sampling of critical drug production areas in the facility.”

The government report, obtained by Bloomberg, said that workers were showing up to the factory barefoot or were not wearing protective gear in sterile areas while one person was observed combing their hair amidst cleaning equipment and others were forging the dates on products attesting to their sterility.

This factory in Mumbai India allegedly has ‘insanitary’ conditions that has led to contaminated eyedrops, according to an FDA inspection report seen by Bloomberg.
via Pharma Technology

The FDA did not immediately respond for comment but a spokesman told Bloomberg, “The agency proactively worked with retailers to have these products removed from the market before any known injuries arose,” Jeremy Kahn said in an email. “We urge consumers to stop using these products, as it could result in an eye infection.”

It’s the second time US authorities found problems with eyedrops made in India.

In February, health agents found that another eyedrop maker in India was linked to infections and to four deaths and 18 cases of vison loss in the US.

There has been an “alarming” rise in the number of eyedrops sold in the US that may cause health problems, according to the Dry Eye Foundation.
Jeffrey Greenberg/Universal Images Group via Getty Images

In that outbreak involving eyedrops from EzriCare LLC and Delsam Pharma LLC – that were recalled – a dangerous bacteria was found in the products, according to another investigation by Bloomberg.

Four people had their eyeballs removed to stop the spread of the bacteria while others experienced cloudy abscesses on their corneas, discharges from their eyes and migraines that lasted for months.

The contaminated eyedrops made their way to the US because of a lapse in the FDA’s supervision of over-the-counter medicines that allowed “two inexperienced entrepreneurs” in India to sell their products to distributors and pharmacists in the US, according to the report.

The FDA issued a warning in October about 26 brands of eyedrops that could cause infections or even blindness, including the Velocity brand.
Velocity Pharma

India bills itself as the “pharmacy to the world” because it is home to most of the pharmaceutical manufacturing.

However, the FDA has little power to force a drugmaker to recall its products.

But it did ban the Kilitch factory on Oct. 23 from sending more eyedrops to the US after inspecting the plant for a week, according to Bloomberg.

The agency also asked Kilitch to recall its products but it hasn’t so far, according to the outlet.

Many eyedrops are manufactured in India, which bills itself as the “pharmacy of the world.”
UCG/Universal Images Group via Getty Images

The FDA has warned consumers about 78 over-the-counter eyedrops this year, but only 13 have been recalled, according to the Dry Eye Foundation, a non-profit in Seattle. 

The group raised a warning flag back in April when it alerted the public about a “sharp rise in eye drops marketed in the US that may pose health risks to consumers.”

In August, the FDA issued a warning about a “life-threatening infection” associated with Dr. Berne’s Organic Castor Oil Eye Drops; and Dr. Berne’s MSM Mist 15% Solution.

The FDA said the contaminated eyedrops could lead to “minor to serious” infections that could potentially affect vision and even “progress to a life-threatening infection.”

Check out our Latest News and Follow us at Facebook

Original Source

‘Pharma Bro’ Martin Shkreli booted from his company by activist revolt

Convicted “Pharma Bro” Martin Shkreli has finally been ousted as boss of the pharmaceutical company he founded, The Post has learned.

Activist shareholders booted the group of directors still loyal to Shkreli during the annual general meeting of Turing’s parent company, Vyera, on Thursday.

Shkreli rose to notoriety after he hiked the price of life-saving AIDS treatment Daraprim to $750 a pill from $17.50 after obtaining the exclusive rights to it in 2015.

The “Pharma Bro” is notorious for hiking the price of life-saving drug Daraprim.
Bloomberg via Getty Images

“The plan is to remove Martin from the company, right the price of Daraprim to pre-Shkreli levels, and do what’s right first with patients, physicians then shareholders,” Jason Aryeh, a longtime activist who previously sought to wrest control of the company, told The Post.

Shkreli was sentenced to seven years in prison in 2017 after being convicted of securities fraud while running two hedge funds.

The victory for the activists comes after a fraught and lengthy proxy battle. In June 2021, Aryeh and other activist investors failed — with the 39-year-old fraudster voting his shares from prison. 

This time, however, Shkreli was banned by Vyera from voting his shares. Still, it wasn’t a slam dunk the activists would win. They feared the current directors — who owned an estimated 44% — could pull tricks like issuing themselves new shares.

The new group takes over a company in disarray, insiders told The Post.

As of June, Turing had “just $23 million in cash, down from $50 million the previous quarter” Aryeh said. “No idea what they’re doing — they burned through $27 million… where did it go?”

“The plan is to liquidate any remaining assets and return money to shareholders,” Aryeh added. “There’s going to be more skeletons they’re going to uncover — my guess is it’ll go defunct eventually.”

Derek Abbott, a bankruptcy lawyer who has been appointed as the legal “receiver” led the charge in this proxy battle. Abbott declined to comment.

In December, the Federal Trade Commission accused Shkreli in court of using anticompetitive tactics to drive up the price of Daraprim. The feds won, resulting in Shkreli being banned from the pharmaceutical industry in the US.

However, because Vyera is based in Switzerland — and subject to Swiss laws — the FTC ban was not enforceable.

Shkreli was sprung from prison in May and moved to a halfway house, from where he is expected to be released Sept. 14. 

He also was banned from Twitter in 2017 for “targeted harassment” of a journalist.

After his early release from prison, Shkreli quipped on Facebook: “Getting out of real prison is easier than getting out of Twitter prison.”

Check out our Latest News and Follow us at Facebook

Original Source

Exit mobile version